Cargando…

Effectiveness of Intravitreal Injection of Ranibizumab for Neovascular Age-Related Macular Degeneration with Serous Pigment Epithelial Detachment

BACKGROUND: We sought to observe the effectiveness of intravitreal injection of ranibizumab in treating neovascular age-related macular degeneration (nAMD) with serous pigment epithelial detachment (sPED). MATERIAL/METHODS: A retrospective, noncomparative case series was performed. Twenty-3 eyes of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Chun, Zhang, Zhen, Chen, Lei, Wang, Fang, Xu, Ding
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793636/
https://www.ncbi.nlm.nih.gov/pubmed/26972376
http://dx.doi.org/10.12659/MSM.895528
_version_ 1782421407601262592
author Zhao, Chun
Zhang, Zhen
Chen, Lei
Wang, Fang
Xu, Ding
author_facet Zhao, Chun
Zhang, Zhen
Chen, Lei
Wang, Fang
Xu, Ding
author_sort Zhao, Chun
collection PubMed
description BACKGROUND: We sought to observe the effectiveness of intravitreal injection of ranibizumab in treating neovascular age-related macular degeneration (nAMD) with serous pigment epithelial detachment (sPED). MATERIAL/METHODS: A retrospective, noncomparative case series was performed. Twenty-3 eyes of 23 patients with sPED secondary to nAMD who had received intravitreal injections of ranibizumab were included in this study. All patients underwent best-corrected visual acuity (BCVA), synchronous fluorescein fundus angiography (FFA), indocyanine green angiography (ICGA), and optical coherence tomography (OCT) examinations. All patients were treated with pro re nata intravitreal injections after 3 loading doses of ranibizumab and were followed up for 12 months. The differences in the BCVAs, maximum PED heights, PED volumes and CFTs of the affected eyes were compared between the baseline and last visit. RESULTS: Twelve months after the first injection, improved visual acuity was observed in 16 of the 23 eyes. 4 eyes exhibited stable visual acuity, and 3 eyes exhibited impaired visual acuity. The mean post-injection logMAR BCVA was 0.58±0.05, which was much better than that at baseline (0.76±0.08; t=1.751, P=0.0869). The mean maximum PED height at baseline was 350.17±35.73μm and it was decreased to 238.87±36.87μm (t=2.192, P=0.0337) at the last visit. The mean PED volume after injection was 0.34±0.1 mm(3), which was significantly decreased compared with that at baseline (0.81±0.21 mm(3); t=2.021, P=0.0494).The mean CFT decreased, but this difference was not statistically significant (t=1.003, P=0.3211). None of the patients exhibited endophthalmitis, uveitis or RPE tears. CONCLUSIONS: Intravitreal injection of ranibizumab for the treatment of neovascular age-related macular degeneration with serous pigment epithelial detachment safely and effectively improved the patients’ visual acuities and decreased their PED heights volumes.
format Online
Article
Text
id pubmed-4793636
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-47936362016-03-29 Effectiveness of Intravitreal Injection of Ranibizumab for Neovascular Age-Related Macular Degeneration with Serous Pigment Epithelial Detachment Zhao, Chun Zhang, Zhen Chen, Lei Wang, Fang Xu, Ding Med Sci Monit Clinical Research BACKGROUND: We sought to observe the effectiveness of intravitreal injection of ranibizumab in treating neovascular age-related macular degeneration (nAMD) with serous pigment epithelial detachment (sPED). MATERIAL/METHODS: A retrospective, noncomparative case series was performed. Twenty-3 eyes of 23 patients with sPED secondary to nAMD who had received intravitreal injections of ranibizumab were included in this study. All patients underwent best-corrected visual acuity (BCVA), synchronous fluorescein fundus angiography (FFA), indocyanine green angiography (ICGA), and optical coherence tomography (OCT) examinations. All patients were treated with pro re nata intravitreal injections after 3 loading doses of ranibizumab and were followed up for 12 months. The differences in the BCVAs, maximum PED heights, PED volumes and CFTs of the affected eyes were compared between the baseline and last visit. RESULTS: Twelve months after the first injection, improved visual acuity was observed in 16 of the 23 eyes. 4 eyes exhibited stable visual acuity, and 3 eyes exhibited impaired visual acuity. The mean post-injection logMAR BCVA was 0.58±0.05, which was much better than that at baseline (0.76±0.08; t=1.751, P=0.0869). The mean maximum PED height at baseline was 350.17±35.73μm and it was decreased to 238.87±36.87μm (t=2.192, P=0.0337) at the last visit. The mean PED volume after injection was 0.34±0.1 mm(3), which was significantly decreased compared with that at baseline (0.81±0.21 mm(3); t=2.021, P=0.0494).The mean CFT decreased, but this difference was not statistically significant (t=1.003, P=0.3211). None of the patients exhibited endophthalmitis, uveitis or RPE tears. CONCLUSIONS: Intravitreal injection of ranibizumab for the treatment of neovascular age-related macular degeneration with serous pigment epithelial detachment safely and effectively improved the patients’ visual acuities and decreased their PED heights volumes. International Scientific Literature, Inc. 2016-03-14 /pmc/articles/PMC4793636/ /pubmed/26972376 http://dx.doi.org/10.12659/MSM.895528 Text en © Med Sci Monit, 2016 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License
spellingShingle Clinical Research
Zhao, Chun
Zhang, Zhen
Chen, Lei
Wang, Fang
Xu, Ding
Effectiveness of Intravitreal Injection of Ranibizumab for Neovascular Age-Related Macular Degeneration with Serous Pigment Epithelial Detachment
title Effectiveness of Intravitreal Injection of Ranibizumab for Neovascular Age-Related Macular Degeneration with Serous Pigment Epithelial Detachment
title_full Effectiveness of Intravitreal Injection of Ranibizumab for Neovascular Age-Related Macular Degeneration with Serous Pigment Epithelial Detachment
title_fullStr Effectiveness of Intravitreal Injection of Ranibizumab for Neovascular Age-Related Macular Degeneration with Serous Pigment Epithelial Detachment
title_full_unstemmed Effectiveness of Intravitreal Injection of Ranibizumab for Neovascular Age-Related Macular Degeneration with Serous Pigment Epithelial Detachment
title_short Effectiveness of Intravitreal Injection of Ranibizumab for Neovascular Age-Related Macular Degeneration with Serous Pigment Epithelial Detachment
title_sort effectiveness of intravitreal injection of ranibizumab for neovascular age-related macular degeneration with serous pigment epithelial detachment
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793636/
https://www.ncbi.nlm.nih.gov/pubmed/26972376
http://dx.doi.org/10.12659/MSM.895528
work_keys_str_mv AT zhaochun effectivenessofintravitrealinjectionofranibizumabforneovascularagerelatedmaculardegenerationwithserouspigmentepithelialdetachment
AT zhangzhen effectivenessofintravitrealinjectionofranibizumabforneovascularagerelatedmaculardegenerationwithserouspigmentepithelialdetachment
AT chenlei effectivenessofintravitrealinjectionofranibizumabforneovascularagerelatedmaculardegenerationwithserouspigmentepithelialdetachment
AT wangfang effectivenessofintravitrealinjectionofranibizumabforneovascularagerelatedmaculardegenerationwithserouspigmentepithelialdetachment
AT xuding effectivenessofintravitrealinjectionofranibizumabforneovascularagerelatedmaculardegenerationwithserouspigmentepithelialdetachment